Imagion Biosystems Half-Year Results for the First Half of 2021 and Appendix 4D
1H2021 Highlights: Enrolment for the Phase I HER2 Breast Cancer Study commences Initiation of research for prostate cancer imaging supported by CSIRO funds…
Imagion Biosystems Enters Agreement to Develop Nanocrystals for Treating Breast Cancer
Imagion Biosystems is pleased to announce it has entered into a Joint Development Agreement with Global Cancer Technology (GCT), to develop GCT’s novel…
Quarterly Activity Report and Appendix 4C for 30 June 2021
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2021. The report highlights that during the quarter the…
Presentation Visuals from 28th May 2021 Annual General Meeting
The presentation visuals from the 28th May 2021 Annual General Meeting are now available. Download here.
Imagion Biosystems Receives A$2.6 Million R&D Tax Incentive
Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation…
First Patient Enrolled in Phase I MagSense® HER2+ Breast Cancer Study
This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study. This is an important step for our Phase I…
Bob Proulx Speaks with The Market Herald
The Chairman and CEO of Imagion Biosystems, Bob Proulx, recently spoke with The Market Herald on a significant transaction in the molecular imaging market, and…
Imagion Biosystems and Patrys Limited to Collaborate on Brain Tumor Imaging
Imagion Biosystems is pleased to announce a partnership with the ASX-listed therapeutic antibody development company Patrys Limited. The collaborative research…
Quarterly Activity Report — Period ending 31 March 2021
Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our…
Quarterly Activity Report for 31 March 2021 — Appendix 4C
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 March 2021 (Q1 FY2021).…
